Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response

Journal of Physiology

Volumn 587, Issue 15, 2009, Pages 3869-3883

  Benedetti, Fabrizio ^a,b,c   Lanotte, Michele ^a   Colloca, Luana ^a,b   Ducati, Alessandro ^a   Zibetti, Maurizio ^a   Lopiano, Leonardo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b National Institute of Neuroscience   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; PLACEBO;

ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; ELECTRODE; GLOBUS PALLIDUS; HUMAN; HUMAN CELL; HUMAN TISSUE; NERVE CELL; NERVE CELL MEMBRANE POTENTIAL; NERVOUS SYSTEM ELECTROPHYSIOLOGY; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; THALAMUS; TREATMENT RESPONSE; ANTERIOR VENTRAL LATERAL THALAMUS; BRAIN ELECTROPHYSIOLOGY; BRAIN NERVE CELL; CONNECTOME; FIRING RATE; INTERNAL GLOBUS PALLIDUS; MUSCLE RIGIDITY; PARKINSON DISEASE; PLACEBO EFFECT; SUBSTANTIA NIGRA PARS RETICULATA; THALAMUS VENTRAL NUCLEUS; VENTRAL ANTERIOR THALAMUS;

AGED; ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; DRUG THERAPY; ELECTROPHYSIOLOGICAL PHENOMENA; FEMALE; GLOBUS PALLIDUS; HUMANS; MALE; MIDDLE AGED; NERVE NET; NEURONS; PARKINSON DISEASE; PLACEBO EFFECT; PSYCHOTHERAPY; SUBSTANTIA NIGRA; SUBTHALAMUS; THALAMUS; TREATMENT OUTCOME;

EID: 68149161222     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2009.169425     Document Type: Article

References (61)

1. Albin RL, Young AB & Penney JB (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci 12, 366-375.
2. Amanzio M & Benedetti F (1999). Neuropharmacological dissection of placebo analgesia: Expectation activated opioid systems versus conditioning-activated specific subsystems. J Neurosci 19, 484-494.
3. Benarroch EE (2008). Subthalamic nucleus and its connections: Anatomic substrate for the network effects of deep brain stimulation. Neurology 70, 1991-1995.
4. Benazzouz A, Gao DM, Ni ZG, Piallat B, Bouali-Benazzouz R & Benabid AL (2000). Effect of high-frequency stimulation of the subthalamic nucleus on the neuronal activities of the substantia nigra pars reticulata and ventrolateral nucleus of the thalamus in the rat. Neuroscience 99, 289-295.
5. Benazzouz A & Hallett M (2000). Mechanism of action of deep brain stimulation. Neurology 55(Suppl. 6), S13-S17.
6. Benedetti F (2008a). Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 48, 33-60.
7. Benedetti F (2008b). Placebo Effects: Understanding the Mechanisms in Health and Disease. Oxford University Press, Oxford.
8. Benedetti F, Colloca L, Torre E, Lanotte M, Melcarne A, Pesare M, Bergamasco B & Lopiano L (2004). Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci 7, 587-588.
9. Benedetti F, Mayberg HS, Wager TD, Stohler CS & Zubieta JK (2005). Neurobiological mechanisms of the placebo effect. J Neurosci 25, 10390-10402.
10. Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S & Rainero I (2003). Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 23, 4315-4323.
11. Bergman H, Wichmann T, Karmon B & DeLong MR (1994). The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72, 507-520.
12. Blandini F, Nappi G, Tassorelli C & Martignoni E (2000). Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62, 63-88.
13. Bolam JP, Hanley JJ, Booth PAC & Bevan MD (2000). Synaptic organisation of the basal ganglia. J Anat 196, 527-542.
14. Brown P (2003). Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. Mov Disord 18, 357-363.
15. Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Di Lazzaro V (2001). Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease. J Neurosci 21, 1033-1038.
16. Colloca L & Benedetti F (2005). Placebos and painkillers: Is mind as real as matter? Nat Rev Neurosci 6, 545-552.
17. Colloca L & Benedetti F (2006). How prior experience shapes placebo analgesia. Pain 124, 126-133.
18. Deep Brain Stimulation for Parkinson's Disease Study Group (2001). Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. New Engl J Med 345, 956-963.
19. de la Fuente-Fernandez R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ & Stoessl AJ (2002). Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 136, 359-363.
20. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB & Stoessl AJ (2001). Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease. Science 293, 1164-1166.
21. DeLong MR (1990). Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13, 281-285.
22. DeLong MR & Wichmann T (2007). Circuits and circuit disorders of the basal ganglia. Arch Neurol 64, 20-24.
23. Enck P, Benedetti F & Schedlowski M (2008). New insights into the placebo and nocebo responses. Neuron 59, 195-206.
24. Fahn S, Elton RL, & the Members of the UPDRS Development Committee (1987). Unified Parkinson's disease rating scale. In Recent Developments in Parkinson's Disease, ed. Fahn S, Marsden CD & Calne DB, pp. 153-163. MacMillan, London.
25. Francois C, Tande D, Yelnik J & Hirsch EC (2002). Distribution and morphology of nigral axons projecting to the thalamus in primates. J Comp Neurol 447, 249-260.
26. Garcia L, D'Alessandro G, Bioulac B & Hammond C (2005). High-frequency stimulation in Parkinson's disease: More or less? Trends Neurosci 28, 209-216.
27. Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Warren Olanow C, Rascol O & Russ H (2008). Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 23, 700-707.
28. Goetz CG, Leurgans S & Raman R (2002). Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord 17, 283-288.
29. Goetz CG, Leurgans S, Raman R & Stebbins GT (2000). Objective changes in motor function during placebo treatment in PD. Neurology 54, 710-714.
30. Hammond C, Bergman H & Brown P (2007). Pathological synchronization in Parkinson's disease: Networks, models and treatments. Trends Neurosci 30, 357-364.
31. Hoehn MW & Yahr MD (1967). Parkinsonism: Onset, progression, and mortality. Neurology 17, 427-442.
32. Illinsky IA & Kultas-Illinsky K (2001). Neuroanatomical organization and connections of the motor thalamus in primates. In Basal Ganglia and Thalamus in Health and Movement Disorders, ed. Kultas-Illinsky K & Illinsky IA, pp. 267-274. Kluwer Academic/Plenum Publishers, Norwell, MA, USA.
33. Lanotte M, Lopiano L, Torre E, Bergamasco B, Colloca L & Benedetti F (2005). Expectation enhances autonomic responses to stimulation of the human subthalamic limbic region. Brain Behav Immun 19, 500-509.
34. Levine JD, Gordon NC & Fields HL (1978). The mechanism of placebo analgesia. Lancet 2, 654-657.
35. Levy R, Dostrovsky JO, Lang AE, Sime E, Hutchinson WD & Lozano AM (2001). Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J Neurophysiol 86, 249-260.
36. Levy R, Hutchinson WD, Lozano AM & Dostrowsky JO (2000). High-frequency synchronization of neuronal activity in the subthalamic nucleus of parkinsonian patients. J Neurosci 20, 7766-7775.
37. Levy R, Hutchinson WD, Lozano AM & Dostrowsky JO (2002). Synchronised neuronal discharge in the basal ganglia of parkinsonian patients is limited to oscillatory activity. J Neurosci 22, 2855-2861.
38. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D & Benabid AL (1998). Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 339, 1105-1111.
39. Magnin M, Morel A & Jeanmonod D (2000). Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients. Neuroscience 96, 549-564.
40. Maltete D, Jodoin N, Karachi C, Houeto JL, Navarro S, Cornu P, Agid Y & Welter ML (2007). Subthalamic stimulation and neuronal activity in the substantia nigra in Parkinson's disease. J Neurophysiol 97, 4017-4022.
41. Maurice N, Thierry AM, Glowinski J & Deniau JM (2003). Spontaneous and evoked activity of substantia nigra pars reticulata neurons during high-frequency stimulation of the subthalamic nucleus. J Neurosci 23, 9929-9936.
42. Mercado R, Constantoyannis C, Mandat T, Kumar A, Schulzer M, Stoessl AJ & Honey CR (2006). Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Mov Disord 21, 1457-1461.
43. Nini A, Feingold A, Slovin H & Bergman H (1995). Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism. J Neurophysiol 74, 1800-1805.
44. Pacheco-Lopez G, Engler H, Niemi MB & Schedlowski M (2006). Expectations and associations that heal: Immunomodulatory placebo effects and its neurobiology. Brain Behav Immun 20, 430-446.
45. Petrovic P, Kalso E, Petersson KM & Ingvar M (2002). Placebo and opioid analgesia - imaging a shared neuronal network. Science 295, 1737-1740.
46. Pollack AE (2001). Anatomy, physiology, and pharmacology of the basal ganglia. Neurol Clin 19, 523-534.
47. Pollo A, Torre E, Lopiano L, Rizzone M, Lanotte M, Cavanna A, Bergamasco B & Benedetti F (2002). Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 13, 1383-1386.
48. Price DD, Craggs J, Verne GN, Perlstein WM & Robinson ME (2007). Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients. Pain 127, 63-72.
49. Price DD, Finniss DG & Benedetti F (2008). A comprehensive review of the placebo effect: Recent advances and current thought. Annu Rev Psychol 59, 565-590.
50. Schaltenbrand G & Wahren W (1977). Atlas for Stereotaxy of the Human Brain. Thieme, New York.
51. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA & Zubieta JK (2007). Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 55, 325-336.
52. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA & Zubieta JK (2008). Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiat 65, 220-231.
53. Shetty N, Friedman JH, Kieburtz K, Marshall FJ & Oakes D (1999). The placebo response in Parkinson's disease. Parkinson Study Group. Clin Neuropharmacol 22, 207-212.
54. Shi LH, Luo F, Woodward D & Chang JY (2006). Basal ganglia neural responses during behaviorally effective deep brain stimulation of the subthalamic nucleus in rats performing a treadmill locomotion test. Synapse 59, 445-457.
55. Stefani A, Bassi A, Mazzone P, Pierantozzi M, Gattoni G, Altibrandi MG, Giacomini P, Peppe A, Bernardi G & Stanzione P (2002). Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: Lack of clear evidence for the 'indirect pathway'. Clin Neurophysiol 113, 91-100.
56. Strafella AP, Ko JH & Monchi O (2006). Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: The contribution of expectation. Neuroimage 31, 1666-1672.
57. Tai CH, Boraud T, Bezard E, Bioulac B, Gross C & Benazzouz A (2003). Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata. FASEB J 17, 1820-1830.
58. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, Kosslyn SM, Rose RM & Cohen JD (2004). Placebo-induced changes in fMRI in the anticipation and experience of pain. Science 303, 1162-1167.
59. Wager TD, Scott DJ & Zubieta JK (2007). Placebo effects on human μ-opioid activity during pain. Proc Natl Acad Sci U S A 104, 11056-11061.
60. Williams D, Tijssen M, Van Bruggen G, Bosch A, Insola A, Di Lazzaro V, Mazzone P, Oliviero A, Quartarone A, Speelman H & Brown P (2002). Dopamine dependent changes in the functional connectivity between basal ganglia and cerebral cortex in the human. Brain 125, 1558-1569.
61. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, Nichols TE & Stohler CS (2005). Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 25, 7754-7762.